B-CELL LYMPHOMA

This study tests whether adding sonrotoclax to the standard drug zanubrutinib helps adults with mantle cell lymphoma that has returned or stopped responding to prior therapy. About 300 participants will receive either the combination or a placebo plus zanubrutinib. The main goal …

This study tests whether giving specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, is safe and effective for people with relapsed or hard-to-treat blood cancers like leukemia, lymphoma, and multiple myeloma. About 80 participants will…

This early-stage study tests a new type of immune cell therapy (BAFF-R CAR-T) in 30 adults with a specific form of B-cell lymphoma that has come back or not responded to treatment. The main goal is to see if the treatment is safe and tolerable. Participants receive a single infus…

This study tests a two-drug approach for adults newly diagnosed with follicular or marginal zone lymphoma, types of B-cell lymphoma. Participants first receive mosunetuzumab alone, then may get lenalidomide added if the cancer only partially responds. The goal is to see how many …

This pilot study tests whether giving fecal microbiota transplants (FMT) to people with lymphoma or leukemia is safe and doable while they undergo CAR-T therapy or stem cell transplants. The goal is to see if FMT can help patients tolerate these powerful cancer treatments better.…

This early-stage trial tests a new treatment called U01 (ssCART-19) for people with B-cell lymphoma that has returned or stopped responding to standard therapy. The treatment uses a patient's own immune cells, modified to better attack cancer cells. The study will enroll 30 parti…

This study tests a new treatment for children and young adults (ages 3-39) with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 …

This study tests a combination of two drugs, pembrolizumab and all-trans retinoic acid (ATRA), in adults with Hodgkin or B-Non-Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to see if the combo is safe and can shrink tumors. About 24 particip…

This study is for people with a type of blood cancer called B-cell lymphoma that has returned or not improved with standard treatments. Researchers are testing a new gene therapy (LCAR02) that targets a protein called CD19 on cancer cells. Up to 18 adults will receive the treatme…

This study tests a new type of immune cell therapy (CD19-CAR.p40-T) for people with blood cancers like lymphoma and leukemia that have not responded to standard treatment or have returned. About 10 adults aged 18 to 75 will receive chemotherapy followed by an infusion of their ow…

This study tests a combination of four drugs (mosunetuzumab, polatuzumab, tafasitamab, and lenalidomide) in people with relapsed B-cell non-Hodgkin lymphoma. The goal is to see if this mix can shrink or control the cancer. About 36 adults with follicular lymphoma or diffuse large…

This study tests whether adding a targeted drug called polatuzumab vedotin after a stem cell transplant can safely control B-cell and Hodgkin lymphoma. About 20 adults whose lymphoma has returned or not responded to prior treatment will take part. The goal is to see if the drug c…

This study tests a combination of two drugs (zanubrutinib and rituximab) plus other medicines for people with a rare, life-threatening immune condition called HLH that happens alongside B-cell lymphoma. The goal is to control the overactive immune response and improve survival. A…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. The drug works like a guided missile, targeting a protein (CD19) on cancer cells to deliver a toxic payload. The study aims to find…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…

This study is for people whose B-cell cancers (like certain lymphomas) have come back or not responded to treatment. It tests a new drug called BGB-16673, which breaks down a protein that helps cancer grow, combined with other cancer drugs. The goal is to find safe doses and see …

This study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene-editing to create donor T-cells that can target and kill cancer cells. The trial w…

This early-phase trial tests an experimental oral drug called LP-168 in adults with B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow the cancer. About 200 partic…

This study tests whether giving two powerful cell therapies together can control large B cell lymphoma that has returned or not responded to first treatment. About 40 adults will receive the drugs axicabtagene ciloleucel and glofitamab. The goal is to manage the disease, not to c…

This study tests a combination of two drugs, rituximab and zanubrutinib, in people with untreated follicular lymphoma or marginal zone lymphoma. The goal is to see how well the combo works and if it is safe. About 43 participants will receive the treatment, and researchers will m…

This early-phase trial is testing a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells…

This study looks at whether adding early palliative care to standard treatment helps people with multiple myeloma or aggressive B-cell lymphoma feel better. About 144 patients and their caregivers will be randomly assigned to receive either usual care alone or usual care plus ear…

This study looks at how the body handles venetoclax when the tablet is crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured. The…